SR9009 10 (Stenabolic)

ACTIVE HALF-LIFE 4-6 hours
CLASSIFICATION PPAR alpha modifier
DOSAGE 20-30 mg/day
MANUFACTURER Deus Medical
LAB TEST See Document
WAREHOUSE EU Warehouse 2
SUBSTANCE Stenabolic ,

Stenabolic (SR 9009) is a PPAR alpha modifier drug that was still being developed as of 2015. It was created by Professor Thomas Burris at the Scripps Research Institute. Notably, it is marketed as both a SARM and a research chemical, and it shares some similarities with Cardarine (GW-501516) since both act as agonists of Rev-ErbA. An article from "National Medicine" indicates that Stenabolic improves exercise capacity in mice by increasing the number of mitochondria in skeletal muscle. This is why it has gained recognition online as “exercise in a bottle.”

As previously noted, Stenabolic has the capability to modify the activity of skeletal muscle mitochondria, effectively enhancing metabolic activity. This quality draws comparisons to DNP, although SR 9009 is considered much safer and does not hinder endurance objectives. Furthermore, unlike DNP, SR 9009 can simulate the benefits of aerobic exercise without the need for actual training, thereby improving endurance rather than diminishing it.

SR 9009 binds to a protein called Rev-erbA, which plays a significant role in regulating fat and sugar metabolism in the liver, fat cell production, and the body’s inflammatory responses. This interaction enhances the effectiveness of your current exercise routine, meaning even a sedentary lifestyle won’t impede your goals. Ultimately, the aim is to utilize the energy from consumed food rather than storing it as fat—something SR 9009 accomplishes effectively by also targeting and burning existing fat stores.

Stenabolic (SR 9009) can help individuals become leaner and improve their cardio endurance, allowing them to cover more distance without becoming fatigued quickly. Overall, it enhances VO2 max, resulting in better endurance performance.

Additionally, SR 9009 can offer advantages to non-athletes by helping reverse obesity, metabolic syndrome, and type 2 diabetes.

Researchers used mice that had low muscle mass, a slow metabolic rate, and limited running ability—essentially, they were analogous to out-of-shape humans. After administering Stenabolic, both their muscle mass and metabolic rates improved, even without any exercise. Once the mice were allowed to run, they were able to run 50% farther without experiencing fatigue.

Unlike fat burners, thyroid enhancers, or appetite suppressants (like clenbuterol, T3, or specific stimulants), SR 9009 does not induce a crash or fatigue. However, since Stenabolic is relatively new and has not been extensively used by human athletes, more research is needed to identify any potential adverse effects.

The recommended dosage for Stenabolic is between 20-30 milligrams (mg) per day, with the option to adjust by 10 mg based on individual preference. Typical cycles last from 6 to 8 weeks, and stacking SR 9009 with Cardarine (GW-501516) is advisable for enhanced endurance benefits.

A significant drawback of Stenabolic in comparison to Cardarine is its short half-life; therefore, it needs to be taken 3-4 times daily. However, some users on forums have reported successful results with dosing it 2-3 times per day.